Plain-English translation of NCT05257018 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing R-CDOP—a modified chemotherapy combination—combined with methotrexate injected into the spinal fluid to prevent a serious type of aggressive lymphoma from coming back in the brain. About 83 patients with high-risk diffuse large B-cell lymphoma will receive this treatment over several months, with regular scans to monitor how well it's working.
When aggressive B-cell lymphoma spreads to the brain, it is often fatal with a very short survival time. While standard chemotherapy helps many patients, some people at high risk still develop brain relapse. This trial is testing whether the new medication combination can significantly reduce that risk.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy infusions and spinal fluid injections every 3 weeks for a total of 6 to 8 cycles (4 to 6 months). After 4 cycles, you'll have a PET scan to see how well the treatment is working, and the number of remaining cycles will be adjusted based on your response. You'll have regular blood tests and heart monitoring throughout the study.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China